SEC Filing Summary: India Globalization Capital, Inc. (IGC Pharma, Inc.)
Business Context and Reporting Period
This Form 8-K Current Report, dated September 15, 2009, discloses a material event for India Globalization Capital, Inc. (also referenced as IGC Pharma, Inc. in the request metadata). The filing details a private placement of equity securities to institutional investors intended to raise capital. The company is incorporated in Maryland and maintains its principal executive offices in Bethesda, Maryland.
Key Financial Metrics and Transaction Details
The filing outlines a specific capital raise transaction rather than periodic financial performance metrics. Key transaction figures include:
- Total Proceeds: $4.5 million.
- Securities Issued: 1,599,000 shares of common stock and warrants to purchase up to 319,800 shares.
- Purchase Price: $1.25 per unit (one share of common stock plus one warrant).
- Warrant Terms: Exercise price of $1.60 per share; exercisable for a period of three years from issuance.
- Placement Agent Fees: Source Capital Group, Inc. received an 8% cash fee of gross proceeds plus reimbursement of certain actual expenses.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, existing debt levels, or general liquidity positions outside of this specific transaction.
Material Changes and Outlook
The primary material change is the execution of a securities purchase agreement on September 15, 2009. The closing of the offering was expected to occur on or before September 18, 2009. The company issued a press release on September 16, 2009, to announce the offering.
Management commentary is limited to the mechanics of the offering and the inclusion of forward-looking statements regarding the anticipated closing. The filing explicitly states that risks and uncertainties are detailed in the company's Form 10-K and Form 10-Q filings. No specific guidance on future revenue or earnings is provided in this document.
Investor Verification Checklist
- Verify the final closing date of the offering and confirmation of the $4.5 million gross proceeds.
- Review the company's most recent Form 10-Q or 10-K to assess current liquidity and debt levels prior to this capital raise.
- Confirm the identity of the institutional investors participating in the offering.
- Examine the "Opinion of Seyfarth Shaw LLP" (Exhibit 5.1) for any legal contingencies related to the issuance.
- Monitor subsequent filings for the actual issuance of the 1,599,000 shares and 319,800 warrants.